Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data.
Details
Serval ID
serval:BIB_887EC15BAE4A
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data.
Journal
Journal of Clinical Oncology
ISSN
1527-7755 (Electronic)
ISSN-L
0732-183X
Publication state
Published
Issued date
2011
Peer-reviewed
Oui
Volume
29
Number
18
Pages
2590-2597
Language
english
Notes
Publication types: Comparative Study ; Journal Article ; Meta-Analysis ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Abstract
PURPOSE: Controversy exists regarding whether or not amifostine might reduce the efficacy of cancer treatment. The aim of this meta-analysis was to evaluate the impact of amifostine on overall survival (OS) and progression-free survival (PFS) in patients treated with radiotherapy or chemoradiotherapy.
MATERIAL AND METHODS: Updated data from individual patients with non-small-cell lung cancer, head and neck squamous cell carcinoma, and pelvic cancer treated with radiotherapy or chemoradiotherapy and randomly assigned to amifostine or not were included. The primary end point was OS.
RESULTS: Twenty-two randomized trials (2279 patients) were potentially eligible. Data were available for 16 trials (1554 patients), but four trials (435 patients) were excluded after data checking. Ultimately 12 trials and 1119 patients were analyzed. A total of 431 patients were treated with radiotherapy alone (three trials), and 688 patients were treated with chemoradiotherapy (nine trials). Thirty-three percent of patients had lung cancers, 65% had head and neck cancers, and 2% had pelvic carcinomas. Ninety-one percent of patients had locally advanced disease (early stage, 9%). Median follow-up was 5.2 years. The hazard ratio (HR) of death was 0.98 (95% CI, 0.84 to 1.14; P = .78). On the basis of 11 trials (1091 patients), the HR of progression, relapse, or death was 1.05 (95% CI, 0.90 to 1.22; P = .53). The tests for heterogeneity were not significant (P ≥ .73), and there was no significant variation of treatment effect according to sex, age, tumor site, stage, histology, locoregional treatment, or type of administration for either end point.
CONCLUSION: Amifostine did not reduce OS and PFS in patients treated with radiotherapy or chemoradiotherapy.
MATERIAL AND METHODS: Updated data from individual patients with non-small-cell lung cancer, head and neck squamous cell carcinoma, and pelvic cancer treated with radiotherapy or chemoradiotherapy and randomly assigned to amifostine or not were included. The primary end point was OS.
RESULTS: Twenty-two randomized trials (2279 patients) were potentially eligible. Data were available for 16 trials (1554 patients), but four trials (435 patients) were excluded after data checking. Ultimately 12 trials and 1119 patients were analyzed. A total of 431 patients were treated with radiotherapy alone (three trials), and 688 patients were treated with chemoradiotherapy (nine trials). Thirty-three percent of patients had lung cancers, 65% had head and neck cancers, and 2% had pelvic carcinomas. Ninety-one percent of patients had locally advanced disease (early stage, 9%). Median follow-up was 5.2 years. The hazard ratio (HR) of death was 0.98 (95% CI, 0.84 to 1.14; P = .78). On the basis of 11 trials (1091 patients), the HR of progression, relapse, or death was 1.05 (95% CI, 0.90 to 1.22; P = .53). The tests for heterogeneity were not significant (P ≥ .73), and there was no significant variation of treatment effect according to sex, age, tumor site, stage, histology, locoregional treatment, or type of administration for either end point.
CONCLUSION: Amifostine did not reduce OS and PFS in patients treated with radiotherapy or chemoradiotherapy.
Keywords
Adult, Aged, Amifostine/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carcinoma/drug therapy, Carcinoma/mortality, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/mortality, Combined Modality Therapy, Disease-Free Survival, Female, Head and Neck Neoplasms/drug therapy, Head and Neck Neoplasms/mortality, Humans, Lung Neoplasms/drug therapy, Lung Neoplasms/mortality, Male, Middle Aged, Neoplasms/drug therapy, Neoplasms/mortality, Radiation Injuries/etiology, Radiation Injuries/prevention & control, Radiation-Protective Agents/therapeutic use, Radiotherapy/adverse effects, Randomized Controlled Trials as Topic/statistics & numerical data, Treatment Failure, Uterine Cervical Neoplasms/drug therapy, Uterine Cervical Neoplasms/mortality
Pubmed
Web of science
Create date
01/12/2014 17:03
Last modification date
20/08/2019 14:47